Нехирургические методы лечения болезни Пейрони

Автор: Красняк Степан Сергеевич

Журнал: Экспериментальная и клиническая урология @ecuro

Статья в выпуске: 3, 2020 года.

Бесплатный доступ

Введение. По различным оценкам болезнь Пейрони (БП) поражает приблизительно 3-9% мужчин во всем мире и может проявляться болью, эректильной дисфункцией и деформацией полового члена, включая его укорочение. Это состояние оказывает значительное негативное влияние на качество жизни, самооценку и психологическое благополучие. Цель. Изучить опубликованные на май 2020 года данные по наиболее эффективным и безопасным методам медикаментозного и иного нехирургического лечения болезни Пейрони. Материалы и методы. Были проанализированы результаты поиска по научным базам данных PubMed, MEDLINE, Embase по запросам «болезнь Пейрони», «медикаментозное лечение», «нехирургическое лечение», «инъекционная терапия». Было найдено 2532 научные публикации, после исключения дубликатов, литературных обзоров, материалов конференции для детального анализа отобрано 74 работы, включенные в настоящий обзор. Результаты. Нехирургическое лечение, включая пероральную, тракционную, ударно-волновую и локальную инъекционную терапии, может позволить пациентам избежать осложнений, связанных с хирургическим вмешательством, и достичь улучшенных функциональных и эстетических результатов. В настоящее время при лечении БП используются несколько вариантов нехирургического лечения, которые могут уменьшить или стабилизировать как объективные показатели (например, длину и деформацию полового члена), так и субъективные показатели (включая сексуальную функцию, боль и удовлетворенность партнера). Выводы. Пероральная терапия может включать в себя пара-аминобензойную кислоту, D-а-токоферол и L-карнитин, в качестве инъекционной терапии могут быть рекомендованы верапамил, клостридиальная коллагеназа. Экстракорпоральная ударно-волновая терапия может быть использована в Российской Федерации в рамках клинических исследований.

Еще

Болезнь пейрони, парааминобензойная кислота, тракционная терапия, пероральная терапия

Короткий адрес: https://sciup.org/142225705

IDR: 142225705 | DOI: 10.29188/2222-8543-2020-12-3-95-102

Список литературы Нехирургические методы лечения болезни Пейрони

Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, et al. Evidence-based management guidelines on peyronie's disease. J Sex Med 2016;13(6):905-23. DOI: 10.1016/j.jsxm.2016.04.062
Hatzichristodoulou G, Lahme S. Peyronie's disease. In: Urology at a Glance 2014. p. 225-36. DOI: 10.1007/978-3-642-54859-8_44
Stuntz M, Perlaky A, Des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronies disease in the United States: A population-based study. PLoS One 2016;11(2). DOI: 10.1371/journal.pone.0150157
Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of peyronie's disease: Prevalence and treatment patterns in the United States. Adv Urol 2011; DOI: 10.1155/2011/282503
Tal R, Hall MS, Alex B, Choi J, Mulhall JP. Peyronies Disease in Teenagers. J Sex Med 2012;9(1):302-8. DOI: 10.1111/j.1743-6109.2011.02502.x
Moreland RB, Nehra A. Pathophysiology of Peyronie's disease. Int J Impot Res 2002;14(5):406-10.
DOI: 10.1038/sj.ijir.3900875
Zargooshi J. Trauma as the cause of Peyronie's disease: penile fracture as a model of trauma. J Urol 2004;172(1):186-8.
DOI: 10.1097/01.ju.0000132144.71458.86
Herati AS, Pastuszak AW. The Genetic Basis of Peyronie Disease: A Review. Sex Med Rev 2016;4(1):85-94.
DOI: 10.1016/j.sxmr.2015.10.002
Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with peyronie's disease. J Urol 2002;168(3):1075-9. 10.1016/ S0022-5347(05)64578-8
DOI: 10.1016/S0022-5347(05)64578-8
Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie's Disease: AUA Guideline. J Urol [Internet]. 2015 Sep [cited 2019 Jun 7];194(3):745-Available from: http://www.jurology.com/doi/. 10.1016/ j.juro.2015.05.098
DOI: 10.1016/j.juro.2015.05.098
Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol 1959;81(6):770-2.
DOI: 10.1016/S0022-5347(17)66108-1
Hauck EW, Bschleipfer T, Haag SM, Rohde V, Weidner W Einschatzung der verschiede-nen konservativen Therapieverfahren der Induratio penis plastica unter deutschen Urolo-genAssessment among German urologists of various conservative treatment modalities for Peyronie's disease. Urologe 2005;44(10):1189-96.
DOI: 10.1007/s00120-005-0867-8
Carson CC. Potassium para-aminobenzoate for the treatment of Peyronies disease: is it effective? Tech Urol [Internet]. 1997 [cited 2019 Jun 7];3(3):135-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9422444
Weidner W, Hauck EW, Schnitker J, Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium Paraaminobenzoate (POTABATM) in the Treatment of Peyronie's Disease: A Prospective, Placebo-Controlled, Randomized Study. Eur Urol 2005;47(4):530-6.
DOI: 10.1016/j.eururo.2004.12.022
Hasche-Klinder R. [Treatment of peyronie's disease with para-aminobenzoacidic potassium (POThBA) (author's transl)]. Urologe A 1978;17(4):224-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/308273
Riley A. Peyronie's disease-a report on a series of 18 patients treated with potassium para-aminobenzoate. BR J Sex Med 1979;6:29-33.
Sikka SC, Hellstrom WJG. Role of oxidative stress and antioxidants in Peyronie's disease. Int J Impot Res 2002;18;14(5):353-60.
DOI: 10.1038/sj.ijir.3900880
Tasanarong A, Kongkham S, Duangchana S, Thitiarchakul S, Eiam-Ong S. Vitamin E ameliorates renal fibrosis by inhibition of TGF-beta/Smad2/3 signaling pathway in UUO mice. J Med Assoc Thai 2011; 94 Suppl 7:S1-9.
Haas AL, Boscoboinik D, Mojon DS, Bohnke M, Azzi A. Vitamin E Inhibits Proliferation of Human Tenon's Capsule Fibroblasts in vitro. Ophthalmic Res 1996;28(3):171-5.
DOI: 10.1159/000267899
Godbout JP, Berg BM, Krzyszton C, Johnson RW a-Tocopherol attenuates NFkB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide- induced sickness behavior. J Neuroimmunol 2005 [cited 2019 Jun 7];169(1-2):97-105.
DOI: 10.1016/j.jneuroim.2005.08.003
Jiang Q, Yin X, Lill MA, Danielson ML, Freiser H, Huang J. Long-chain carboxychro-manols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. Proc Natl Acad Sci [Internet]. 2008 [cited 2019 Jun 7];105(51):20464-9.
DOI: 10.1073/pnas.0810962106
Fazzio A, Marilley D, Azzi A. The effect of alpha-tocopherol and beta-tocopherol on proliferation, protein kinase C activity and gene expression in different cell lines. Biochem Mol Biol Int [Internet]. 1997 [cited 2019 Jun 7];41(1):93-101.
DOI: 10.1080/15216549700201101
Halal AA, Geavlete P, Ceban E. Pharmacological therapy in patients diagnosed with Peyronie's disease. J Med Life 2012
Paulis G, Brancato T, D'Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, et al. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology 2013;1(1):120-8.
DOI: 10.1111/j.2047-2927.2012.00007.x
Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of peyronie's disease: A nationwide survey. J Sex Med 2008;5(4):954-64.
DOI: 10.1111/j.1743-6109.2007.00674.x
Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: New insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol 2005;2(6):291-7
DOI: 10.1038/ncpuro0201
Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of Vitamin E and Propi-onyl-L-Carnitine, Separately or in Combination, in Patients With Early Chronic Peyronie's Disease: A Double-Blind, Placebo Controlled, Randomized Study. J Urol 2007;178(4):1398-403.
DOI: 10.1016/j.juro.2007.05.162
Kohei H, Hisasue S, Ryuichi K. Outcome analysis for conservative management of Peyronie's disease. Int J Urol 2006;13(3):244-7.
DOI: 10.1111/j.1442-2042.2006.01270.x
Paulis G, Paulis A, Romano G, Barletta D, Fabiani A. Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: Results of clinical application. Res Reports Urol 2017;9:129-39.
DOI: 10.2147/RRU.S141748
Scardino PL, Scott WW the Use of Tocopherols in the Treatment of Peyronie'S Disease. Ann N YAcad Sci 1949;52(3):390-6.
DOI: 10.1111/j.1749-6632.1949.tb55300.x
Chesney J. Peyronie's disease. Br J Urol 1975;47:209-18.
Pryor J, Farrell C. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol Med 1983;9:41-5.
Devine CJ, Horton C. Bent penis. Semin Urol 1987;5:251-61.
Vaz FM, Wanders RJA. Carnitine biosynthesis in mammals. Biochem J [Internet]. 2002 [cited 2019 Jun 14];361(3):417. :3610417
DOI: 10.1042/0264-6021
Jack GS, Gonzalez-Cadavid N, Rajfer J. Conservative management options for Peyronie's disease. Curr Urol Rep [Internet]. 2005 [cited 2019 Jun 14];6(6):454-60.
DOI: 10.1007/s11934-005-0041-2
Ge P, Cui Y, Liu F, Luan J, Zhou X, Han J. L-carnitine affects osteoblast differentiation in NIH3T3 fibroblasts by the IGF-1/PI3K/Akt signalling pathway. Biosci Trends 2015;9(1):42-8.
DOI: 10.5582/bst.2015.01000
Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. BJU Int 2001;88(1):63-7. 10.1046/ j.1464-410X.2001.02241.x
DOI: 10.1046/j.1464-410X.2001.02241.x
Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002;89(9):895-900.
DOI: 10.1046/j.1464-410X.2002.02738.x
Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int 2010;106(2):240-8.
DOI: 10.1111/j.1464-410X.2009.09041.x
Valente EGA, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-Argi-nine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003;9(4):229-44. 10.1016/ j.niox.2003.12.002
DOI: 10.1016/j.niox.2003.12.002
Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: A case-control study. Res Reports Urol 2015;8:1-10.
DOI: 10.2147/RRU.S97194
Gur S, Limin M, Hellstrom WJG. Current status and new developments in Peyronie's disease: Medical, minimally invasive and surgical treatment options. Expert Opin Phar-macothe 2011;12(6):931-44.
DOI: 10.1517/14656566.2011.544252
Akkus E, Breza J, Carrier S, Kadioglu A, Rehman J, Lue TE. Is colchicine effective in Peyronie'sdisease? A pilot study. Urology 1994;44(2):291-5. 10.1016/ S0090-4295(94)80155-X
DOI: 10.1016/S0090-4295(94)80155-X
Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: A randomized double-blind, placebo-controlled study. Int J Impot Res2004;16(3):238-43.
DOI: 10.1038/sj.ijir.3901185
Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int 2003;91(6):522-4. 10.1046/ j.1464-410X.2003.04134.x.
DOI: 10.1046/j.1464-410X.2003.04134.x
Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991;25(2):89-94.
DOI: 10.3109/00365599109024539
Hellstrom WJG, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon a-2b for Minimally Invasive Treatment for Peyronie's Disease. J Urol 2006;176(1):394-8.
DOI: 10.1016/S0022-5347(06)00517-9
Stewart CA, Yafi FA, Knoedler M, Mandava SH, McCaslin IR, Sangkum P, et al. Intralesional injection of interferon-a2b improves penile curvature in men with Peyronie's disease independent of plaque location. J Urol 2015;194(6):1704-7.
DOI: 10.1016/j.juro.2015.06.096
Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman 0. Effect of intralesional inter-feron-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: A randomized and prospective study. Urology 2006;67(5):1038-42.
DOI: 10.1016/j.urology.2005.11.005
Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982;10(3):135-40.
DOI: 10.1007/BF00255956
Gelbard M, Goldstein I, Hellstrom WJG, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190(1):199-207.
DOI: 10.1016/j.juro.2013.01.087
Cordon BH, Osmonov D, Hatzichristodoulou G, Morey AF. Peyronie's penile plication. Transl Androl Urol 2017;6(4):639-644.
DOI: 10.21037/tau.2017.07.18
Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical Safety and Effectiveness of Collagenase Clostridium Histolyticum Injection in Patients with Peyronie's Disease: A Phase 3 Open-Label Study. J Sex Med 2015;12(1):248-58.
DOI: 10.1111/jsm.12731
Yang KK, Bennett N. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms. Urology 2016;94:143-7.
DOI: 10.1016/j.urology.2016.04.049
Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJG. Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease. J Sex Med 2016;13(4):684-9.
DOI: 10.1016/j.jsxm.2016.02.105
Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994;151(6):1522-4.
DOI: 10.1016/S0022-5347(17)35291-6
Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single-blind study. Urology 1998;51(4):620-6.
DOI: 10.1016/S0090-4295(97)00700-0
Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intrale-sional verapamil for treatment of Peyronie's disease: A randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009;41(3):467-71;
DOI: 10.1007/s11255-009-9522-4
Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y, et al. Nicardipine vs. Saline injection as treatment for peyronie's disease: A prospective, randomized, singleblind trial. J Sex Med 2010;7(11):3743-9.
DOI: 10.1111/j.1743-6109.2010.01924.x
Bellorofonte C, Ruoppolo M, Tura M, Zaatar C, Tombolini P, Menchini Fabris GF. Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis. Arch Ital di Urol Nefrol Androl organo Uff dell"Associazione per la Ric Urol = Arch Ital Urol Nefrol Androl 1989;61(4):417-22
Strebel RT, Suter S, Sautter T, Hauri D. Extracorporeal shockwave therapy for Peyronie's disease does not correct penile deformity. Int J Impot Res 2004;16(5):448-51.
DOI: 10.1038/sj.ijir.3901192
Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: Results of a prospective approach. J Urol 2004;171(1):296-9.
DOI: 10.1097/01.ju.0000099891.68488.4e
Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie's disease: Results of a prospective randomized controlled doubleblind trial. BJU Int 2010;106(9):1352-6.
DOI: 10.1111/j.1464-410X.2010.09331.x
Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in peyronie's disease: Results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med 2013;10(11):2815-21.
DOI: 10.1111/jsm.1227565
Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A First Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Extracor-poreal Shock Wave Therapy for the Treatment of Peyronie's Disease. Eur Urol 2009;56(2):363-70.
DOI: 10.1016/j.eururo.2009.05.012
Fojecki GL, Tiessen S, Osther PJS. Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie's disease, erectile dysfunction and chronic pelvic pain. World J Urol 2017;35(1):1-9.
DOI: 10.1007/s00345-016-1834-2
Gao L, Qian S, Tang Z, Li J, Yuan J. A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease. Int J Impot Res 2016 Sep;28(5):161-6
DOI: 10.1038/ijir.2016.24
Fode M, Hatzichristodoulou G, Serefoglu EC, Verze P, Albersen M. Low-intensity shockwave therapy for erectile dysfunction: Is the evidence strong enough? Nat Rev Urol 2017 Oct;14(10):593-606.
DOI: 10.1038/nrurol.2017.119
Corona G, Boddi V, Balercia G, Rastrelli G, De Vita G, Sforza A, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010;7(4 PART 1):1547-56.
DOI: 10.1111/j.1743-6109.2009.01698.x
Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, et al. Penile traction therapy with the new device ‘Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study. BJU Int 2019;123(4):694-702.
DOI: 10.1111/bju.14602
Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T, et al. Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, SingleBlind, Controlled Trial. J Urol 2019;202(3):599-610.
DOI: 10.1097/JU.0000000000000245
Joseph J, Ziegelmann M, Savage J, Meng Y, Kohler T, Trost L. 170 6-month Outcomes of RestoreX Penile Traction Therapy in Men with Peyronie's Disease: A Randomized, Controlled Trial. J Sex Med 2019;16(4):S86.
DOI: 10.1016/j.jsxm.2019.01.179
Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU Int 2010;106(8):1178-80.
DOI: 10.1111/j.1464-410X.2010.09365.x

Еще

Статья научная